Van ECK Associates Corp Has $1.28 Million Stock Holdings in Insulet Co. (NASDAQ:PODD)

Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD) by 2.1% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,903 shares of the medical instruments supplier’s stock after selling 105 shares during the quarter. Van ECK Associates Corp’s holdings in Insulet were worth $1,280,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC increased its stake in shares of Insulet by 1.7% during the 3rd quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after purchasing an additional 42 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Insulet by 1.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock worth $1,146,000 after purchasing an additional 43 shares during the last quarter. Glenmede Trust Co. NA increased its stake in shares of Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares during the last quarter. Graypoint LLC increased its stake in shares of Insulet by 5.3% during the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB increased its stake in shares of Insulet by 9.6% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after purchasing an additional 47 shares during the last quarter.

Analyst Ratings Changes

PODD has been the subject of several recent analyst reports. Stifel Nicolaus upped their price objective on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a report on Friday. Morgan Stanley upped their price objective on shares of Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a report on Monday, November 11th. Piper Sandler upped their price objective on shares of Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a report on Friday. Citigroup upped their price objective on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday. Finally, Sanford C. Bernstein initiated coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective for the company. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $289.06.

Insulet Price Performance

NASDAQ:PODD opened at $282.80 on Friday. The company has a 50-day moving average of $272.98 and a 200-day moving average of $247.11. The company has a market capitalization of $19.84 billion, a price-to-earnings ratio of 48.42, a PEG ratio of 3.56 and a beta of 1.23. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. The company had revenue of $597.50 million during the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 21.22% and a return on equity of 27.98%. As a group, equities research analysts anticipate that Insulet Co. will post 3.22 earnings per share for the current fiscal year.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Lauren Budden sold 915 shares of the stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $275.62, for a total transaction of $252,192.30. Following the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The disclosure for this sale can be found here. 0.47% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.